Fierce Biotech July 23, 2024
A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases.
Sanjaya Singh, Ph.D., a co-inventor of AbbVie’s autoimmune blockbuster Skyrizi, founded Third Arc after bringing his time as global head of J&J’s Janssen Biotherapeutics to an end in 2021. Singh hired Joe Erhardt, Ph.D., formerly global head of oncology discovery and external innovation at J&J, to serve as the chief operating officer of Third Arc in 2023.
With Singh taking the chief scientific officer post, Third Arc needed a CEO and once again looked to J&J. Peter Lebowitz, M.D., Ph.D., took the top seat in January, ending...
Today's Sponsors
Today's Sponsor